Unicycive Therapeutics Stock Filter Stocks by Fundamentals
| UNCY Stock | USD 0.69 0.01 1.47% |
Unicycive Therapeutics fundamentals help investors to digest information that contributes to Unicycive Therapeutics' financial success or failures. It also enables traders to predict the movement of Unicycive Stock. The fundamental analysis module provides a way to measure Unicycive Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Unicycive Therapeutics stock.
Unicycive | Shares Owned by Institutions |
Unicycive Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Unicycive Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Unicycive Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Unicycive Therapeutics' value.| Shares | Bleakley Financial Group Llc | 2024-09-30 | 80 K | Xtx Topco Ltd | 2024-09-30 | 70.8 K | Blackrock Inc | 2024-06-30 | 51.8 K | State Street Corp | 2024-06-30 | 43.9 K | Northern Trust Corp | 2024-09-30 | 24 K | Captrust Financial Advisors | 2024-06-30 | 18.8 K | Tower Research Capital Llc | 2024-06-30 | 18.5 K | Tandem Capital Management Corp | 2024-09-30 | 15.5 K | Virtu Financial Llc | 2024-06-30 | 11.1 K | Octagon Capital Advisors Lp | 2024-09-30 | 8.6 M | Logos Global Management Lp | 2024-06-30 | 6.9 M |
Unicycive Fundamentals
| Return On Equity | -1.22 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 38.82 M | ||||
| Shares Outstanding | 103.8 M | ||||
| Shares Owned By Insiders | 6.73 % | ||||
| Shares Owned By Institutions | 38.20 % | ||||
| Number Of Shares Shorted | 1.26 M | ||||
| Price To Book | 2.53 X | ||||
| Price To Sales | 62.82 X | ||||
| Revenue | 675 K | ||||
| EBITDA | (30.18 M) | ||||
| Net Income | (30.54 M) | ||||
| Cash And Equivalents | 10.57 M | ||||
| Cash Per Share | 0.70 X | ||||
| Total Debt | 811 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.43 X | ||||
| Book Value Per Share | (0.11) X | ||||
| Cash Flow From Operations | (18.28 M) | ||||
| Short Ratio | 0.74 X | ||||
| Earnings Per Share | (0.46) X | ||||
| Target Price | 5.5 | ||||
| Number Of Employees | 14 | ||||
| Beta | 2.29 | ||||
| Market Capitalization | 70.36 M | ||||
| Total Asset | 14.19 M | ||||
| Retained Earnings | (64.54 M) | ||||
| Working Capital | (4.13 M) | ||||
| Net Asset | 14.19 M |
About Unicycive Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Unicycive Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Unicycive Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Unicycive Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.